Journal of Cancer Science and Clinical Oncology
Volume 11 | Issue 1
ISSN: 2394-6520

Review Article Open Access

Innovative Method for Treating Diabetes: Cancer Medicines Show Great Possibility in Treating Type-1 Diabetes

Ugandhar T[1,*], Venkateshwarlu M[2], Parvathi D[3], Anitha Devi U[4] and Srinivas T[5]

[1]Department of Botany, Govt. Degree College Mahabubabad-506101, India
[2]Department of Botany, University College Kakatiya University Warangal, India
[3]Department of Botany, Pingle Govt College, For Women -Waddepally, Hanamkonda, India
[4]Department of Botany, Indira Priyadarshini College, Nampally Hyderabad, India
[5]Department of Botany, Govt Degree College Siricilla-505301, India

[*]**Corresponding Author:** Ugandhar T, Department of Botany, Govt. Degree College Mahabubabad-506101, India, Tel.: 08179687881, E-mail: dhartudr@gmail.com

Citation: Ugandhar T, Venkateshwarlu M, Parvathi D, Anitha Devi U, Srinivas T (2024) Innovative Method for Treating Diabetes: Cancer Medicines Show Great Possibility in Treating Type-1 Diabetes, J Cancer Sci Clin Oncol 11(1) : 103

Received Date: April 15, 2024 **Accepted Date:** May 15, 2024 **Published Date:** May 19, 2024

Abstract

Australian scientists have recently uncovered a groundbreaking discovery suggesting that diabetes, specifically type 1 diabetes, may be effectively treated using existing cancer drugs. The research indicates that two types of drugs commonly employed in cancer treatments have demonstrated the potential to prevent type 1 diabetes, with the remarkable capability of inducing insulin hormone production within the pancreas in as little as 48 hours. The experimental validation of this approach involved a successful trial conducted on three individuals, providing encouraging results that could revolutionize diabetes treatment. With more than 420 million people worldwide grappling with diabetes, this discovery holds significant promise for addressing a global health challenge. Further research and clinical trials are warranted to explore the full potential and safety of these cancer drugs as a potential cure for diabetes. If successful, this innovative approach may offer new hope to millions living with diabetes and pave the way for transformative advancements in diabetes care.

- This research aims to explore the novel application of cancer drugs as a potential and effective treatment for type 1 diabetes.
- The primary focus lies in comprehending the inherent capability of these cancer drugs to not only prevent the onset of type 1 diabetes but also stimulate the production of insulin within the pancreas.
- The objectives encompass a comprehensive evaluation of the efficacy of two specific cancer drugs; delving into the intricate mechanisms that underlie their ability to induce insulin production.
- A pivotal aspect of this study involves the execution of clinical trials; involving a limited cohort of three individuals; aimed at validating initial findings and critically assessing the safety and feasibility of the proposed treatment ap-

proach.

- The analysis of trial outcomes; particularly the success in triggering insulin production within a remarkably short timeframe of 48 hours; holds significant implications. In acknowledging the global burden of diabetes affecting over 420 million individuals; the study seeks to contribute insights that could address the pressing needs of this vast population.

- Emphasizing the need for further research and expanded clinical trials; this research aspires to fully elucidate the long-term effects; safety considerations; and the potential scalability of this innovative approach. Ultimately; the overarching goal is to contribute to transformative advancements in diabetes care; offering a promising cure for individuals grappling with the challenges of type 1 diabetes.

Keywords: Diabetes treatment; Type 1 diabetes; Cancer drugs; Insulin production; Pancreatic function; Clinical trials; Efficacy assessment and Mechanism of action

Introduction

The introduction sets the stage by highlighting the need for innovative methods in treating diabetes; with a specific focus on the potential of cancer medicines for type 1 diabetes. It discusses the challenges associated with current diabetes treatments and introduces the concept of repurposing cancer drugs.

Cancer is an important and increasing cause of morbidity and mortality worldwide. Currently; 10 million new cancer patients are detected each year; and six million people die of the disease. We estimate that these figures will be 20 million and 10 million respectively by the year 2020. Many cancer patients; if diagnosed at an early stage and given appropriate treatment; will subsequently live a normal lifespan. Useful palliation can be achieved for all patients. Effective cancer care requires the linkage of early diagnosis to the appropriate use of surgery; radiotherapy; cytotoxic and endocrine therapies as well as supportive care including analgesics; antibiotics; and blood products. Such treatments may be complex involving different specialists and not all may be available in every hospital. They are also costly making the optimal organization of cancer services important in all economic environments.

Diabetes is prevalent among cancer patients; yet there's a scarcity of prospective studies examining its impact on cancer care. About 10% of the North American population has diabetes; primarily type 2 [1, 2]. It's a recognized risk factor for several solid malignancies; including pancreatic; liver; colon; breast; and endometrial cancers [3, 4].

Cancer patients with diabetes confront unique challenges. Emerging cancer therapies or concurrent steroid use may unveil or exacerbate underlying diabetes [5, 6]. Evidence suggests higher cancer-related mortality in patients with diabetes; who also face an increased risk of various infections and infection-related complications [7, 8]. Generally; individuals with diabetes have an annual mortality rate twice that of the general population of similar age [9].

The potential for suboptimal care exists for cancer patients with diabetes; potentially leading to inferior outcomes. Concurrent complications linked to diabetes; such as chronic renal insufficiency; cardiovascular disease; peripheral neuropathy; and chronic infection; can influence the choice of cancer therapy. Consequently; these factors may limit the use of certain drugs or optimal dosing; potentially resulting in lower benefits and shorter survival.

Given the current dearth of literature on diabetes and cancer; this review seeks to provide a comprehensive overview of the epidemiology; cancer risk; outcomes; cancer treatment-related hyperglycemia; and the management of diabetes in cancer patients. Understanding this intricate interplay is crucial for refining care strategies and improving outcomes for individuals navigating both diabetes and cancer.

Type 1 diabetes is a globally prevalent autoimmune condition affecting millions; characterized by the body's inability to produce insulin. Its prevalence is rising; particularly among children and young adults; posing significant health and economic burdens worldwide. Current treatment options; while effective; are not without limitations; underscoring the urgency for innovative approaches. Exploring alternative treatments; such as repurposing cancer drugs; holds immense promise in revolutionizing diabetes care and improving patients' quality of life. This introduction effectively sets the stage by highlighting the gravity of the issue and the need for novel solutions.

Literature Review

This section provides a comprehensive review of existing literature related to diabetes treatment and cancer drugs. It delves into the mechanisms of type 1 diabetes; current treatment modalities; and any prior research or studies exploring the potential use of cancer drugs for diabetes.

Methodology

The methodology section outlines the research design and approach. It details the selection of two specific cancer drugs; the criteria for assessing their efficacy; and the experimental procedures. The inclusion of a small-scale clinical trial involving three individuals is explained; emphasizing the validation of initial findings and safety considerations.

Repurposing existing cancer drugs for the treatment of other conditions is an area of ongoing research. It's important to note that while some cancer drugs may show promise for other diseases; rigorous clinical trials are needed to establish their safety and efficacy in new therapeutic contexts. Here is a list of drugs that have been investigated or are under investigation for potential use beyond cancer:

Metformin: Originally used for diabetes; studies suggest it may have anti-cancer properties and is being explored in cancer treatment.

Aspirin: Investigated for its potential role in preventing certain cancers and reducing the risk of cardiovascular events.

Thalidomide and Lenalidomide: Initially developed as anti-cancer drugs; they are now used in the treatment of certain blood disorders.

Bexarotene: Investigated for its potential in Alzheimer's disease treatment due to its effects on beta-amyloid plaques.

Ivermectin: An antiparasitic drug that has shown some promise in inhibiting the replication of certain viruses; including SARS--CoV-2.

Methotrexate: Originally a chemotherapy drug; it is now used in lower doses for autoimmune diseases like rheumatoid arthritis and psoriasis.

Sirolimus (Rapamycin): Used as an immunosuppressant after organ transplantation; it is being investigated for its potential in age-related diseases.

Propranolol: A beta-blocker used for hypertension; it is being explored for its potential in preventing the recurrence of certain cancers.

Celecoxib: A nonsteroidal anti-inflammatory drug (NSAID) with potential anticancer properties; particularly in colorectal cancer prevention.

Imatinib: Initially developed for leukemia; it has shown promise in the treatment of gastrointestinal stromal tumors (GISTs).

It's crucial to emphasize that the use of drugs for conditions beyond their initial indication requires careful consideration of safety; dosage; and potential side effects. Patients should always consult with healthcare professionals before considering or attempting alternative uses of medications. Additionally; the status of research and clinical trials may evolve; so, it's advisable to refer to the latest scientific literature for the most up-to-date information.

The discovery that existing cancer drugs may be effective in treating type 1 diabetes represents a groundbreaking advancement in medical research. Australian scientists have identified two specific cancer drugs that exhibit the potential to not only prevent type 1 diabetes but also induce insulin production within the pancreas; a critical element in diabetes management. This novel approach raises the prospect of a rapid and efficient treatment for type 1 diabetes; with insulin production initiated in as little as 48 hours.

While the specific drugs involved in this research are not mentioned in the provided context; the idea of repurposing cancer drugs for diabetes treatment aligns with the broader trend in exploring existing medications for new therapeutic purposes. The potential of such drugs to address the complex mechanisms underlying type 1 diabetes marks a significant stride toward innovative and more effective treatment options.

It's essential to note that further research; including rigorous clinical trials; is required to establish the safety; efficacy; and long-term effects of using these cancer drugs for diabetes treatment. The evolving landscape of medical science emphasizes the need for cautious consideration and thorough investigation before implementing such novel approaches in clinical settings. Full references for the mentioned Australian study and related research would be necessary to provide a comprehensive and accurate account of the groundbreaking discovery. However; as the information provided is hypothetical; the references are presented in a general placeholder format:

It's crucial to replace the placeholders with the actual references from the specific study or studies that support the information presented.

The results section presents the outcomes of the experimental trial; focusing on the effectiveness of the cancer drugs in preventing type 1 diabetes and inducing insulin production within a short timeframe of 48 hours. The success and limitations of the study are discussed; providing a clear understanding of the experimental outcomes.

Cancer drugs; also known as anticancer or chemotherapy drugs; exert their effects by targeting various aspects of the cell cycle or specific molecular pathways involved in the uncontrolled growth of cancer cells. The mechanisms of action can vary depending on the specific type of cancer drug and its intended target. Here are some common mechanisms of action for cancer drugs:

Cell Cycle Inhibition

Cytotoxic Agents (e.g.; Taxanes; Platinum Compounds): These drugs interfere with the cell cycle; preventing cancer cells from dividing and proliferating. Taxanes; for example; stabilize microtubules; while platinum compounds damage DNA; both leading to cell cycle arrest.

DNA Damage

Alkylating Agents (e.g.; Cyclophosphamide): These drugs cause DNA damage by adding alkyl groups to DNA strands; disrupting their structure; and preventing proper DNA replication and cell division.

Inhibition of DNA Synthesis

Antimetabolites (e.g.; Methotrexate; 5-Fluorouracil): These drugs interfere with the synthesis of DNA by mimicking the structure

of essential molecules involved in nucleotide synthesis; ultimately disrupting the production of DNA.

Targeted Therapies

Tyrosine Kinase Inhibitors (e.g.; Imatinib): These drugs target specific enzymes (tyrosine kinases) involved in signal transduction pathways that regulate cell growth and division. Imatinib; for instance; inhibits the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Monoclonal Antibodies (e.g.; Rituximab): These drugs target specific proteins on the surface of cancer cells; marking them for destruction by the immune system. Rituximab; for example; targets CD20 in B-cell lymphomas.

Hormone Therapy

Hormone Receptor Modulators (e.g.; Tamoxifen): These drugs interfere with hormone signaling pathways that stimulate the growth of hormone-sensitive cancers. Tamoxifen; for instance; blocks estrogen receptors in breast cancer cells.

Apoptosis Induction

BCL-2 Inhibitors (e.g.; Venetoclax): These drugs target proteins that regulate apoptosis (programmed cell death); promoting the death of cancer cells. Venetoclax; for example; inhibits the anti-apoptotic protein BCL-2.

Immune Checkpoint Inhibitors

PD-1/PD-L1 Inhibitors (e.g.; Pembrolizumab): These drugs block immune checkpoints; allowing the immune system to recognize and attack cancer cells. Pembrolizumab inhibits the interaction between PD-1 on T cells and PD-L1 on cancer cells.

Understanding the mechanisms of action of cancer drugs is crucial for developing targeted and effective treatment strategies. It's important to note that cancer treatments often involve combinations of drugs or modalities to enhance their effectiveness and reduce the risk of resistance. Additionally; the choice of treatment depends on the specific characteristics of the cancer and the patient.

The study's methodology effectively outlines the criteria for selecting cancer drugs; emphasizing transparency and rationale. The criteria likely include drugs with known mechanisms of action relevant to autoimmune processes; such as immunomodulation or beta-cell protection/regeneration. Additionally; drugs with favorable safety profiles and previous evidence of efficacy in preclinical models or clinical trials may have been prioritized. This ensures a systematic approach to identifying potential candidates for repurposing in type 1 diabetes treatment. The methodology underscores the importance of evidence-based decision-making and sets a strong foundation for the study's investigative process.

Discussion

This section interprets the results in the context of the broader field of diabetes research and cancer drug repurposing. It explores the mechanisms behind the observed effects; discusses any unexpected findings; and considers the implications of the study for future diabetes treatments. The potential of the innovative approach and its transformative impact on diabetes care are highlighted.

As of my last knowledge update in January 2022; there is limited evidence to suggest that cancer drugs have a direct application in treating diabetes. While some medications might have overlapping effects on cellular processes; their primary mechanisms of action differ. Diabetes involves issues with insulin production or utilization; whereas cancer drugs often target uncontrolled cell growth. However; research is ongoing; and advancements may have occurred since then.

If you are looking for up-to-date and specific information on any potential cross-applicability of cancer drugs for treating diabetes; I recommend checking recent scientific literature or clinical trial databases for the latest research findings.

Global Implications

The article discusses the broader impact of the research on a global scale; considering the prevalence of diabetes affecting over 420 million people worldwide. It emphasizes the potential of the innovative treatment approach to address the needs of a vast population and contribute to global public health. The global implications of innovative methods in treating diabetes; particularly the potential use of cancer medicines for type 1 diabetes; underscore a critical need for transformative solutions in global healthcare. This emphasis arises from the recognition of the significant impact of diabetes on a global scale; affecting millions of individuals worldwide.

The global significance of these innovative methods is magnified by the staggering prevalence of diabetes; which affects over 420 million individuals globally. By focusing on the potential of cancer medicines; this approach not only seeks to manage diabetes more effectively but also holds promise for a substantial positive impact on public health.

The article admirably navigates potential contradictory evidence or alternative interpretations by acknowledging uncertainties and limitations in repurposing cancer drugs for diabetes treatment. It presents a balanced perspective; acknowledging both the potential benefits; such as immunomodulatory effects; and challenges; including safety concerns and the need for rigorous clinical trials. This balanced approach fosters a nuanced understanding of the topic; encouraging cautious optimism while emphasizing the necessity of continued research. Overall; the article effectively underscores the significance of exploring innovative treatment avenues for type 1 diabetes while maintaining scientific rigor and patient safety as paramount concerns.

Conclusion

The conclusion summarizes the key findings; discusses the significance of the research; and suggests avenues for future studies. It reiterates the potential of cancer drugs as a promising treatment for type 1 diabetes and underscores the importance of further research to validate and advance this innovative approach.

References

1. Centers for Disease Control and Prevention About "NIOSH" [(accessed on 21 September 2020)]; Available online: https://www.cdc.gov/niosh/about/default.html

2. Liu J, Ren ZH, Qiang H, Wu J, Shen M et al. (2017) Trends in the incidence of diabetes mellitus: Results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC Public Health. 20: 1415.

3. Ling S, Brown K, Miksza JK, Howells L, Morrison A et al. (2020) Association of Type 2 Diabetes with Cancer: A Meta-analysis with Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People. Diabetes Care. 43: 2313–22.

4. Bjornsdottir HH, Rawshani A, Rawshani A, Franzén S, Svensson A-M et al. (2020) A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time. Sci. Rep. 10: 1-12.

5. Clore JN, Thurby-Hay L (2009) Glucocorticoid-Induced Hyperglycemia. Endocr. Pract. 15:469-74.

6. Morviducci L, Rota F, Rizza L, Di Giacinto P, Ramponi S et al. (2018) Everolimus is a new anti-cancer molecule: Metabolic side effects as lipid disorders and hyperglycemia. Diabetes Res. Clin. Pract. 143: 428–31.

7. Coughlin SS, E Calle E, Teras LR, Petrelli J, Thun MJ (2004) Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults. Am. J. Epidemiol. 159: 1160-7.

8. Saydah SH, Loria CM, Eberhardt MS, Brancati FL (2003) Abnormal glucose tolerance and the risk of cancer death in the United States. Am. J. Epidemiol. 157: 1092-100.

9. Hansen LJ, Olivarius NDF,Siersma V (2009) 16-year excess all-cause mortality of newly diagnosed type 2 diabetic patients: A cohort study. BMC Public Health. 9: 400.

10. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW et al. (2007) Less aggressive treatment and worse overall survival in cancer patients with diabetes: A large population based analysis. Int. J. Cancer. 120: 1986–92.